Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience-Reference-Cited by-同舟云学术

Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience

Published:2011-08 Issue:15-16 Volume:16 Page:646-653
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Vanderwall Dana E.,Yuen Nancy,Al-Ansari Mohammad,Bailey James,Fram David,Green Darren V.S.,Pickett Stephen,Vitulli Giovanni,Luengo Juan I.,Almenoff June S.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference19 articles.

1. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat. Rev.,2004

2. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR, and METEOR. SAR & QSAR;Greene;Environ. Res.,1999

3. Identification of structure–activity relationships for adverse effects of pharmaceuticals in humans: part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities;Matthews;Regul. Tox. Pharmacol.,2009

4. Assessment of developmental toxicity potential of chemicals by quantitative structure–toxicity relationship models;Gomba;Chemosphere,1995

5. Mapping adverse drug reactions in chemical space;Schreiber;J. Med. Chem.,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging Data Pathways for Next Generation Safety Monitoring of Medicines and Vaccines;2022 International Conference on Computational Science and Computational Intelligence (CSCI);2022-12

2. Safety of medicines and vaccines – building next generation capability;Trends in Pharmacological Sciences;2021-12

3. Signal Detection in Pharmacovigilance: A Review of Informatics-driven Approaches for the Discovery of Drug-Drug Interaction Signals in Different Data Sources;Artificial Intelligence in the Life Sciences;2021-12

4. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting;Clinical Pharmacology & Therapeutics;2020-11-07

5. Artificial Intelligence, Real-World Automation and the Safety of Medicines;Drug Safety;2020-10-07